How many drugs treat Angina pectoris?

Drug Landscape tracks 10 marketed treatments for Angina pectoris (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/angina-pectoris.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Angina pectoris — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Angina pectoris (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Angina pectoris, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Corlanor	IVABRADINE	Amgen	Hyperpolarization-activated Cyclic Nucleotide-gated Channel Blocker	Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1	2015-01-01
Ranexa	RANOLAZINE	Menarini Intl	Anti-anginal [EPC]	Sodium channel protein type 5 subunit alpha	2006-01-01
Lipitor	atorvastatin	Pfizer Inc.	HMG-CoA reductase inhibitor (statin)	HMG-CoA reductase	1996-12-17
Lipitor	Atorvastatin Calcium	Pfizer	atorvastatin	3-hydroxy-3-methylglutaryl-coenzyme A reductase	1996-01-01
Norvasc	amlodipine	Pfizer Inc.	Calcium channel blocker (dihydropyridine)	Aldehyde oxidase, Voltage-dependent calcium channel gamma-1 subunit, 5-hydroxytryptamine receptor 6	1992-07-31
Cardene	NICARDIPINE	Hikma Intl Pharms	Dihydropyridine Calcium Channel Blocker	Voltage-dependent T-type calcium channel subunit alpha-1H	1988-01-01
Cardizem	diltiazem	Generic (originally Tanabe Seiyaku)	Calcium channel blocker (non-dihydropyridine, benzothiazepine)	Voltage-dependent calcium channel gamma-1 subunit, Multidrug resistance protein 1, Solute carrier family 22 member 1	1982-11-05
Procardia	Nifedipine	Pfizer	Dihydropyridine Calcium Channel Blocker [EPC]	Voltage-dependent L-type calcium channel subunit alpha-1C	1981-01-01
Nitroglycerin	glyceryl trinitrate	Fougera	Nitrate Vasodilator [EPC]	guanylate cyclase	1981-01-01
Tenoretic 100	ATENOLOL	Twi Pharms	beta-Adrenergic Blocker [EPC]	Adenosine receptor A3	1981-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 11 drugs in Angina pectoris
Pfizer · 3 drugs in Angina pectoris
Pfizer Inc. · 2 drugs in Angina pectoris
Fougera · 1 drug in Angina pectoris
Generic (originally Ciba-Geigy/Novartis) · 1 drug in Angina pectoris
Generic (originally ICI/AstraZeneca) · 1 drug in Angina pectoris
Generic (originally Tanabe Seiyaku) · 1 drug in Angina pectoris
Hikma Intl Pharms · 1 drug in Angina pectoris
Menarini Intl · 1 drug in Angina pectoris
Midwest Cardiovascular Research Foundation · 1 drug in Angina pectoris
Twi Pharms · 1 drug in Angina pectoris
University Hospital, Ghent · 1 drug in Angina pectoris

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Angina pectoris:

Cite this brief

Drug Landscape (2026). Angina pectoris — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/angina-pectoris. Accessed 2026-06-10.

Angina pectoris full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing